

# SEARCH REQUEST FORM

Requestor's Name: \_\_\_\_\_ Serial Number: \_\_\_\_\_

Date: \_\_\_\_\_ Phone: \_\_\_\_\_ Art Unit: \_\_\_\_\_

## Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

## STAFF USE ONLY

Date completed: 12-21-01

Searcher: Beverly @ 4994

Terminal time: 71

Elapsed time: \_\_\_\_\_

CPU time: \_\_\_\_\_

Total time: 15

Number of Searches: \_\_\_\_\_

Number of Databases: 1

Search Site	Vendors
<input type="checkbox"/> STIC	<input checked="" type="checkbox"/> IG
<input type="checkbox"/> CM-1	<input type="checkbox"/> STN
<input type="checkbox"/> Pre-S	<input type="checkbox"/> Dialog
<b>Type of Search</b>	<b>APS</b>
<input type="checkbox"/> N.A. Sequence	<input type="checkbox"/> Geninfo
<input type="checkbox"/> A.A. Sequence	<input type="checkbox"/> SDC
<input type="checkbox"/> Structure	<input type="checkbox"/> DARC/Questel
<input type="checkbox"/> Bibliographic	<input type="checkbox"/> Other

Yu, G.  
09/1836868

09/836868

FILE 'REGISTRY' ENTERED AT 09:58:17 ON 21 DEC 2001

E MORINDA CITRIFOLIA/CN

L1 1 SEA ABB=ON PLU=ON "MORINDA CITRIFOLIA, EXT."/CN

FILE 'CAPLUS' ENTERED AT 09:58:46 ON 21 DEC 2001

L2 0 SEA ABB=ON PLU=ON L1

L3 11 S (CITRIFOLIA OR NONI OR INDIAN MULBERR?) (5A) (EXTRACT? OR EXT##)

L3 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:584369 CAPLUS

DOCUMENT NUMBER: 135:352430

TITLE: Two novel glycosides from the fruits of Morinda citrifolia (Noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line

AUTHOR(S): Liu, Guangming; Bode, Ann; Ma, Wei-Ya; Sang, Shengmin; Ho, Chi-Tang; Dong, Zigang

CORPORATE SOURCE: The Hormel Institute, University of Minnesota, Austin, MN, 55912, USA

SOURCE: Cancer Res. (2001), 61(15), 5749-5756

CODEN: CNREA8 ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The fruit juice of Morinda citrifolia (noni), a plant originally grown in the Hawaiian and Tahitian islands, has long been used by islanders to treat diseases, including cancer. Two novel glycosides, 6-O-(.beta.-D-glucopyranosyl)-1-O-octanoyl-.beta.-D-glucopyranose and asperulosidic acid, extd. from the juice of noni fruits, were used to examine their effects on 12-O-tetradecanoylphorbol-13-acetate (TPA)- and epidermal growth factor (EGF)-induced AP-1 transactivation and cell transformation in mouse epidermal JB6 cells. The results indicated that both compds. were effective in suppressing TPA- or EGF-induced cell transformation and assocd. AP-1 activity. TPA- or EGF-induced phosphorylation of c-Jun, but not extracellular signal-regulated kinases or p38 kinases, was also blocked by the compds., indicating that c-Jun N-terminal kinases were crit. in mediating TPA- or EGF-induced AP-1 activity and subsequent cell transformation in JB6 cells.

REFERENCE COUNT: 48

REFERENCE(S): (1) Adler, V; J Biol Chem 1996, V271, P23304

CAPLUS

(2) Agadir, A; J Biol Chem 1999, V274, P29779

CAPLUS

(3) Amstad, P; Carcinogenesis (Lond) 1997, V18, P479 CAPLUS

(4) Angel, P; Biochim Biophys Acta 1991, V1072, P129 CAPLUS

(5) Angel, P; Cell 1987, V49, P729 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:167759 CAPLUS

DOCUMENT NUMBER: 134:192537

TITLE: Morinda citrifolia dietary fiber

INVENTOR(S): Wadsworth, John; Story, Stephen; Jensen, Jarakae

09/836868

PATENT ASSIGNEE(S): Morinda, Inc., USA  
SOURCE: PCT Int. Appl., 14 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015551	A1	20010308	WO 2000-US23489	20000825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6254913	B1	20010703	US 1999-384784	19990827
US 2001046550	A1	20011129	US 2001-829039	20010409

PRIORITY APPLN. INFO.: US 1999-384784 A 19990827

AB A dietary fiber product obtained from the Indian mulberry (*Morinda citrifolia*) plant and the process of extg. and purifying the fiber is disclosed. According to one embodiment, the Indian mulberry pulp is washed and sepd. from the juice by filtration. The wet pulp is pasteurized. The wet pulp can be further processed by drying. High fiber products can be prep'd. by mixing the pulp with ingredients such as supplemental dietary fiber, water, sweeteners, flavoring agents, coloring agents, and nutritional ingredients.

REFERENCE COUNT: 5

REFERENCE(S):  
(1) Gaynor; US 5744187 A 1998  
(2) McGillivray; US 5213836 A 1993  
(3) Meer; US 4996051 A 1991  
(4) Moniz; US 5288491 A 1994  
(5) Thacker; US 5106634 A 1992

L3 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:167753 CAPLUS  
DOCUMENT NUMBER: 134:212475  
TITLE: *Morinda citrifolia* oil  
INVENTOR(S): Wadsworth, John; Story, Stephen  
PATENT ASSIGNEE(S): Morinda, Inc., USA  
SOURCE: PCT Int. Appl., 15 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015537	A1	20010308	WO 2000-US23394	20000825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH,				

App

09/836868

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,  
UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,  
TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,  
BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6214351 B1 20010410 US 1999-384785 19990827

PRIORITY APPLN. INFO.: US 1999-384785 A 19990827

AB An essential oil product obtained from the Indian mulberry *Morinda citrifolia* plant and the process of extg. and purifying the oil is described. According to one embodiment, the seeds from the Indian mulberry fruit are dried, preferably to a moisture content less than 10%. The seeds are ground or shredded to facilitate the removal of natural occurring oil. The shredded or ground seed flakes are pressed to expel *Morinda citrifolia* oil. The remaining seed cake is then mixed with a food grade, non-polar extn. solvent such as hexane. The mixt. is heated for a sufficient length of time to complete the extn. process. The extn. solvent is then evapd. from the mixt. leaving the *Morinda citrifolia* oil. The oil is further refined, bleached, dried, and deodorized to remove free fatty acids and other unwanted components. An antioxidant, such as tocopheryl acetate, Pr gallate, TBHQ, or BHT can optionally be added to stabilize the oil for further processing or packaging.

REFERENCE COUNT: 4

- REFERENCE(S):  
(1) Acosta; US 5922766 A 1999 CAPLUS  
(2) Cooper; US 5736174 A 1998 CAPLUS.  
(3) Goto; US 6139897 A 2000  
(4) Moreau; US 5843499 A 1998 CAPLUS

L3 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:450093 CAPLUS

DOCUMENT NUMBER: 121:50093

TITLE: Isolation of 1-methoxy-2-formyl-3-hydroxyanthraquinone from *Morinda citrifolia* and neoplasm inhibitors containing the same

INVENTOR(S): Umezawa, Kazuo; Imoto, Masaya; Ooba, Shigeru;  
Koyano, Takashi; Komyama, Yoshiko

PATENT ASSIGNEE(S): Umezawa Kazuo, Japan; Tonen Corp

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06087736	A2	19940329	JP 1992-264311	19920907

AB Neoplasm inhibitors contg. the title compd. (I) as an active ingredient are claimed. A method for isolation of I contains extn. of *M. citrifolia* with solvents and the following purifn. A root of *M. citrifolia* (50 g) was ground and extd. 3 times with 200 mL CHCl<sub>3</sub> each at room temp. and the obtained CHCl<sub>3</sub> ext. was freeze-dried to give 0.7 g powder. The powder (200 mg) dispersed in CHCl<sub>3</sub> was fractionated with silica gel column chromatog. eluting with 11:1, 10:1 and 5:1

09/836868

mixts. of hexane and AcOEt to give an active fraction as eluate by the 5:1 mixt. The active fraction was dried, and the obtained 51.8 mg product was dissolved in MeOH to give 35.4 mg insol. fraction, which was crystd. in CH<sub>2</sub>Cl<sub>2</sub> to give 12.6 mg I. IC<sub>50</sub> value of I against K-rasts-NRK cell was 7.50 .μ.g/mL at 33.degree. and 4.95 .μ.g/mL at 39.degree.. I also normalized cell morphol. of cancer cells.

L3 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1994:23170 CAPLUS  
DOCUMENT NUMBER: 120:23170  
TITLE: Induction of normal phenotypes in ras-transformed cells by damnacanthal from *Morinda citrifolia*  
AUTHOR(S): Hiramatsu, Tomonori; Imoto, Masaya; Koyano, Takashi; Umezawa, Kazuo  
CORPORATE SOURCE: Fac. Sci. Technol., Keio Univ., Yokohama, 223, Japan  
SOURCE: Cancer Lett. (Shannon, Irel.) (1993), 73(2-3), 161-6  
CODEN: CALEDQ; ISSN: 0304-3835  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB The authors have screened tropical plant exts. for substances that induce normal morphol. in K-rasts-NRK cells. As a result the authors isolated an anthraquinone compd., damnacanthal, from the chloroform ext. of the root of *Morinda citrifolia*. Damnacanthal induced normal morphol. and cytoskeletal structure in K-rasts-NRK cells at the permissive temp., without changing the amt. and localization of Ras. The effect of damnacanthal was reversible, and the compd. had no effect on the morphol. of RSVts-NRK cells expressing the src oncogene. Thus, damnacanthal is a new inhibitor of ras function. *different*

L3 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1987:623299 CAPLUS  
DOCUMENT NUMBER: 107:223299  
TITLE: Pharmaceuticals containing asperulosidic acid for hepatitis treatment  
INVENTOR(S): Ogata, Yoshitake  
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62132829	A2	19870616	JP 1985-272397	19851205

GI

09/836868



AB Pharmaceuticals for hepatitis treatment contain asperulosidic acid(I). Capsule compns. were prep'd. by mixing I 5, microcryst. cellulose 80, corn starch 20, lactose 22, and polyvinylpyrrolidone 3 g.

L3 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1986:485300 CAPLUS

DOCUMENT NUMBER: 105:85300

TITLE: Separation of glycobismine A from Glycosmis citrifolia

INVENTOR(S): Furukawa, Hiroshi; Sato, Tadashi; Nagai, Yasushi; Kagei, Kengo

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60190780	A2	19850928	JP 1984-43897	19840309

GI



I

09/836868

AB A new alkaloid glycobismine A (I) is isolated from root bark of Glycosmis citrifolia and its mol. structure is elucidated. The compd. is effective in curing skin itching and canker. Thus, dried G. citrifolia root bark (7 kg) was extd. with EtOH. The EtOH ext. was treated with CHCl<sub>3</sub>/H<sub>2</sub>O. The CHCl<sub>3</sub> fraction was concd. to syrup. The syrup was worked up by column chromatog. on silica gel, followed by silica gel TLC sepn. using benzene, diisopropyl ether, ether, acetone, and CHCl<sub>3</sub> as solvents to yield glycobismine A (180 mg).

L3 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1981:27438 CAPLUS  
DOCUMENT NUMBER: 94:27438  
TITLE: Isolation of .beta.-sitosterol and ursolic acid from Morinda citrifolia Linn  
AUTHOR(S): Ahmad, Viqar Uddin; Bano, Shaheen  
CORPORATE SOURCE: HEJ Postgrad. Inst. Chem., Univ. Karachi, Karachi, Pak.  
SOURCE: J. Chem. Soc. Pak. (1980), 2(2), 71  
CODEN: JCSPDF

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Ursolic acid (m.p. 286.degree.) and .beta.-sitosterol (m.p. 140-1.degree.) were isolated from alc. exts. of M. citrifolia leaves. Compd. identity was confirmed by IR and mass spectra as well as by prepns. of derivs.

L3 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1979:520361 CAPLUS  
DOCUMENT NUMBER: 91:120361  
TITLE: Some chemical constituents of Morinda citrifolia  
AUTHOR(S): Levand, Oscar; Larson, Harold O.  
CORPORATE SOURCE: Dep. Chem., Univ. Guam, Agana, 96910, Guam  
SOURCE: Planta Med. (1979), 36(2), 186-7  
CODEN: PLMEA; ISSN: 0032-0943

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB From exts. of dried fruit of M. citrifolia, asperuloside and glucose were identified by their acetyl derivs., i.e. asperuloside tetraacetate (m.p. 152-53.degree.) and .beta.-D-glucopyranose pentaacetate (m.p. 132-33.degree.), resp. Caproic and caprylic acids were also found, but in the steam distillate of ripe, sliced fruit.

L3 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1976:490215 CAPLUS  
DOCUMENT NUMBER: 85:90215  
TITLE: Flavone glycosides from the flowers of Morinda citrifolia  
AUTHOR(S): Singh, Jagdamba; Tiwari, R. D.  
CORPORATE SOURCE: Dep. Chem., Univ. Allahabad, Allahabad, India  
SOURCE: J. Indian Chem. Soc. (1976), 53(4), 424  
CODEN: JICSAH

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Two flavone glycosides were isolated from the hot EtOH ext. of the flowers of M. citrifolia. 5,7-Acacetin-7-O-

09/836868

.beta.-D(+)-glucopyranoside and 5,7-dimethylapigenin-4'-O-.beta.-D(+)-galactopyranoside were identified by chem. means.

L3 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1941:14663 CAPLUS  
DOCUMENT NUMBER: 35:14663  
ORIGINAL REFERENCE NO.: 35:2331i,2332a  
TITLE: The manufacture of "ikat" fabrics on the island of Rotti [Dutch East Indies]  
AUTHOR(S): Buhler, Alfred  
SOURCE: Verhandl. naturforsch. Ges. Basel (1939), Volume Date 1938-1939, 50, 32-97  
DOCUMENT TYPE: Journal  
LANGUAGE: German  
AB Mainly a description of mech. details of native hand-manuf. of these cotton fabrics. Methods of dyeing blue or black with indigo, red with exts. of Morinda citrifolia or of Brazil wood (Caesalpinia sappan), and yellow with mixed exts. of Curcuma domestica with Cudrania javanensis or Loranthus are described. Ext. of other plants are employed as supplementary dyes. 6 references.

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO, CAB, AGRICOLA, CROPU, CROPB, LIFESCI' ENTERED AT 10:02:28 ON 21 DEC 2001)

L4 46 S L3  
L5 33 DUP REM L4 (13 DUPLICATES REMOVED)

L5 ANSWER 1 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS  
ACCESSION NUMBER: 2001:374038 BIOSIS  
DOCUMENT NUMBER: PREV200100374038  
TITLE: Morinda citrifolia dietary fiber and method.  
AUTHOR(S): Wadsworth, John J. (1); Story, Stephen P.; Jensen, C. Jarakae  
CORPORATE SOURCE: (1) Orem, UT USA  
ASSIGNEE: Morinda, Inc., Provo, UT, USA  
PATENT INFORMATION: US 6254913 July 03, 2001  
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (July 3, 2001) Vol. 1248, No. 1, pp. No Pagination. e-file.  
ISSN: 0098-1133.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
AB A dietary fiber product obtained from the Indian mulberry (Morinda citrifolia) plant and the process of extracting and purifying the fiber is disclosed. According to one embodiment, the Indian mulberry pulp is washed and separated from the juice by filtration. The wet pulp is pasteurized. The wet pulp can be further processed by drying. A high fiber products can be prepared by mixing the pulp with ingredients, such as supplemental dietary fiber, water, sweeteners, flavoring agents, coloring agents, and nutritional ingredients.

L5 ANSWER 2 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS  
ACCESSION NUMBER: 2001:443084 BIOSIS  
DOCUMENT NUMBER: PREV200100443084  
TITLE: Morinda citrifolia oil.  
AUTHOR(S): Wadsworth, John J.; Story, Stephen P.

09/836868

ASSIGNEE: Morinda, Inc.

PATENT INFORMATION: US 6214351 April 10, 2001

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 10, 2001) Vol. 1245, No. 2, pp. No Pagination. e-file.  
ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

AB An essential oil product obtained from the Indian mulberry (*Morinda citrifolia*) plant and the process of extracting and purifying the oil is disclosed. According to one embodiment, the seeds from the Indian mulberry fruit are dried, preferably to a moisture content less than 10%. The seeds are ground or shredded to facilitate the removal of natural occurring oil. The shredded or ground flakes are pressed to expel *Morinda citrifolia* oil. The remaining seed cake is then mixed with a food grade, non-polar extraction solvent such as hexane. The mixture is heated for a sufficient length of time to complete the extraction process. The extraction solvent is then evaporated from the mixture leaving the *Morinda citrifolia* oil. The oil is further refined, bleached, dried, and deodorized to remove free fatty acids and other unwanted components. An antioxidant can optionally be added to stabilize the oil for further processing or packaging.

L5 ANSWER 3 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2001-602546 [68] WPIDS

DOC. NO. CPI: C2001-178444

TITLE: Treatment of tinnitus using an extract of Indian mulberry, optionally in combination with other agents such as Ginkgo biloba extract, vitamin C, lycopene or coenzyme Q10.

DERWENT CLASS: B04

INVENTOR(S): GIDLUND, B

PATENT ASSIGNEE(S): (GIDL-I) GIDLUND B

COUNTRY COUNT: 94

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

WO 2001064231	A1	20010907	(200168)*	EN	17
---------------	----	----------	-----------	----	----

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC  
MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE  
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG  
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ  
PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU  
ZA ZW

US 2001033871	A1	20011025	(200170)†
---------------	----	----------	-----------

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001064231	A1	WO 2001-SE447	20010302
US 2001033871	Provisional	US 2000-186356P	20000302
		US 2001-796746	20010302

09/836868

PRIORITY APPLN. INFO: SE 2000-698 20000302; US 2001-796746  
20010302

AN 2001-602546 [68] WPIDS

AB WO 200164231 A UPAB: 20011121

NOVELTY - An extract, which is derived from the fruits, leaves, bark or roots of Morinda citrifolia L. (Indian mulberry), is used for manufacturing a medicament for treatment of tinnitus in mammals.

ACTIVITY - Treatment of tinnitus.

MECHANISM OF ACTION - None given.

USE - The medicament is useful in treatment of tinnitus.

Dwg.0/0

L5 ANSWER 4 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2001-265850 [27] WPIDS

DOC. NO. CPI: C2001-080425

TITLE: Method of obtaining dietary fiber useful in e.g. nutritional products involves filtering wet pulp from juice of fiber plant and pasteurizing pulp.

DERWENT CLASS: A97 D13 E19

INVENTOR(S): JENSEN, C J; STORY, S P; WADSWORTH, J J; JENSEN, J;  
STORY, S; WADSWORTH, J

PATENT ASSIGNEE(S): (MORI-N) MORINDA INC

COUNTRY COUNT: 94

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001015551	A1	20010308	(200127)*	EN	14
RW:	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW				
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW				
AU 2000073335	A	20010326	(200137)		
US 6254913	B1	20010703	(200140)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001015551	A1	WO 2000-US23489	20000825
AU 2000073335	A	AU 2000-73335	20000825
US 6254913	B1	US 1999-384784	19990827

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000073335	A Based on	WO 200115551

PRIORITY APPLN. INFO: US 1999-384784 19990827

AN 2001-265850 [27] WPIDS

AB WO 200115551 A UPAB: 20010518

NOVELTY - Morinda citrifolia (Indian mulberry plant) dietary fiber (A) is obtained by filtering the wet pulp from the juice of Morinda citrifolia (B) and pasteurizing the wet pulp. The pulp has a fiber

09/836868

content of 10-40 wt.%.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a high fiber dietary product comprising pulp of (B), supplemental dietary fiber and a sweetener.

USE - In cosmetics, nutritional products, dietary supplements as a flavoring and as a product itself.

ADVANTAGE - (A) has the nutritional and the health benefits.

Dwg.0/0

L5 ANSWER 5 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
ACCESSION NUMBER: 2001-226656 [23] WPIDS  
DOC. NO. CPI: C2001-067649  
TITLE: Essential oil, used in massage oil, cosmetics and candles, comprises oil **extracted** from Morinda **Citrifolia** seeds.  
DERWENT CLASS: B04 D21 D22 D23  
INVENTOR(S): STORY, S P; WADSWORTH, J J; STORY, S; WADSWORTH, J  
PATENT ASSIGNEE(S): (MORI-N) MORINDA INC  
COUNTRY COUNT: 94  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001015537	A1	20010308 (200123)*	EN	15	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
US 6214351	B1	20010410 (200127)			
AU 2000073331	A	20010326 (200137)			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001015537	A1	WO 2000-US23394	20000825
US 6214351	B1	US 1999-384785	19990827
AU 2000073331	A	AU 2000-73331	20000825

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000073331	A	Based on WO 200115537

PRIORITY APPLN. INFO: US 1999-384785 19990827

AN 2001-226656 [23] WPIDS

AB WO 200115537 A UPAB: 20010425

NOVELTY - Essential oil comprises oil **extracted** from Morinda **Citrifolia** seeds is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the extraction of an essential oil as above comprising: (a) obtaining Morinda **Citrifolia** seeds that are dried to a moisture content of less than 10 %; (b) cracking, flaking or grinding to form ground seeds; and (c) pressing the ground seeds to expel Morinda

09/836868

Citrifolia oil.

USE - The essential oil can be used in massage oils, cosmetics, or candles (claimed).

ADVANTAGE - The oil is easily extracted and can be stored for long periods of time.

Dwg.0/0

L5 ANSWER 6 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2001-510208 [56] WPIDS

DOC. NO. CPI: C2001-152910

TITLE: Bathing composition containing **extract** of Morinda citrifolia.

DERWENT CLASS: D21

PATENT ASSIGNEE(S): (KANE) KANEBO LTD

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 2001213758 A	20010807	(200156)*			4

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 2001213758 A		JP 2000-21470	20000131

PRIORITY APPLN. INFO: JP 2000-21470 20000131

AN 2001-510208 [56] WPIDS

AB JP2001213758 A UPAB: 20011001

NOVELTY - Bathing composition, comprising extract, crushed product or pressed product of Morinda citrifolia.

DETAILED DESCRIPTION - Bathing composition, comprising extract, crushed product or pressed product of Morinda citrifolia and also physically active ingredient.

USE - Useful as bathing agent giving good feeling after using.

Dwg.0/0

L5 ANSWER 7 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2001-609745 [70] WPIDS

DOC. NO. CPI: C2001-181794

TITLE: Hair cosmetics for restoring hair growth and preventing dandruff, comprises extract, powder or pressed material of Morinda citrifolia, as active ingredient.

DERWENT CLASS: D21

PATENT ASSIGNEE(S): (KANE) KANEBO LTD

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 2001213733 A	20010807	(200170)*			9

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

Searcher : Shears 308-4994

09/836868

JP 2001213733 A

JP 2000-21472 20000131

PRIORITY APPLN. INFO: JP 2000-21472 20000131

AN 2001-609745 [70] WPIDS

AB JP2001213733 A UPAB: 20011129

NOVELTY - A hair cosmetics comprises extract, powder or pressed material of *Morinda citrifolia*, as active ingredient.

ACTIVITY - Endocrine-gen; antimicrobial; cytostatic; antiulcer.  
No test details are given in the specification.

MECHANISM OF ACTION - None given.

USE - For restoring hair growth and for preventing dandruff.

ADVANTAGE - The hair cosmetics containing powder,  
extract or pressed material of *Morinda citrifolia*,  
has excellent hair restoring effect and dandruff preventing effect.  
The cosmetics prevents split ends in hairs, effectively improves  
blood circulation and also exhibits excellent antimicrobial effect.

Dwg.0/0

L5 ANSWER 8 OF 33 MEDLINE DUPLICATE 1

ACCESSION NUMBER: 2001431544 MEDLINE

DOCUMENT NUMBER: 21371894 PubMed ID: 11479211

TITLE: Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line.

AUTHOR: Liu G; Bode A; Ma W Y; Sang S; Ho C T; Dong Z

CORPORATE SOURCE: The Hormel Institute, University of Minnesota,  
Austin, MN 55912, USA.

CONTRACT NUMBER: CA74916 (NCI)

CA77646 (NCI)

CA81064 (NCI)

SOURCE: CANCER RESEARCH, (2001 Aug 1) 61 (15) 5749-56.  
Journal code: CNF; 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200108

ENTRY DATE: Entered STN: 20010820

Last Updated on STN: 20010820

Entered Medline: 20010816

AB The fruit juice of *Morinda citrifolia* (noni), a plant originally grown in the Hawaiian and Tahitian islands, has long been used by islanders to treat diseases, including cancer. Two novel glycosides, 6-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose and asperulosidic acid, extracted from the juice of noni fruits, were used to examine their effects on 12-O-tetradecanoylphorbol-13-acetate (TPA)- and epidermal growth factor (EGF)-induced AP-1 transactivation and cell transformation in mouse epidermal JB6 cells. The results indicated that both compounds were effective in suppressing TPA- or EGF-induced cell transformation and associated AP-1 activity. TPA- or EGF-induced phosphorylation of c-Jun, but not extracellular signal-regulated kinases or p38 kinases, was also blocked by the compounds, indicating that c-Jun N-terminal kinases were critical in mediating TPA- or EGF-induced AP-1 activity and subsequent cell transformation

09/836868

in JB6 cells.

L5 ANSWER 9 OF 33 MEDLINE DUPLICATE 2  
ACCESSION NUMBER: 2001328763 MEDLINE  
DOCUMENT NUMBER: 21290190 PubMed ID: 11396135  
TITLE: Modulation of cancer cell multidrug resistance by an extract of *Ficus citrifolia*.  
AUTHOR: Simon P N; Chaboud A; Darbour N; Di Pietro A;  
Dumontet C; Lurel F; Raynaud J; Barron D  
CORPORATE SOURCE: Departement de Botanique, Pharmacognosie,  
Homeopathie, Institut des Sciences Pharmaceutiques et Biologiques, 8 Avenue Rockefeller, 69008 Lyon,  
France.  
SOURCE: ANTICANCER RESEARCH, (2001 Mar-Apr) 21 (2A) 1023-7.  
Journal code: 59L; 8102988. ISSN: 0250-7005.  
PUB. COUNTRY: Greece  
LANGUAGE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: English  
ENTRY MONTH: Priority Journals  
200107  
ENTRY DATE: Entered STN: 20010730  
Last Updated on STN: 20010730  
Entered Medline: 20010726

AB Multidrug resistance due to P-glycoprotein is a serious impediment to successful chemotherapy of cancer. Previous studies have shown that natural compounds such as prenyl flavonoids are able to modulate the multidrug resistance phenotype of P-glycoprotein-positive cancer cells. A fraction from the dichloromethane extract of a common Guadalupe *Ficus*, *Ficus citrifolia* was studied for its direct interaction with the purified C-terminal cytosolic domain of P-glycoprotein, and for its induced accumulation and cytotoxicity of vinblastine and daunomycin in two model cell lines overexpressing P-glycoprotein, namely K562/R7 and MESSA/Dx5. The fraction bound with high affinity to P-glycoprotein C-terminal cytosolic domain and was as efficient as cyclosporin A to increase intracellular accumulation of daunomycin in K562/R7 leukemic cells. Moreover, the fraction markedly enhanced the cytotoxic effect of vinblastine on the growth of MESSA/Dx5 cells. These results suggest that *Ficus citrifolia* possesses important therapeutic potential for improving the efficacy of cancer chemotherapy.

L5 ANSWER 10 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 2001386094 EMBASE  
TITLE: Evaluation of the flora of Puerto Rico for in vitro antiplasmodial and antimycobacterial activities.  
AUTHOR: Antoun M.D.; Ramos Z.; Vazques J.; Oquendo I.;  
Proctor G.R.; Gerena L.; Franzblau S.G.  
CORPORATE SOURCE: Dr. M.D. Antoun, School of Pharmacy, Medical Sciences Campus, University of Puerto Rico, San Juan 00936, Puerto Rico  
SOURCE: Phytotherapy Research, (2001) 15/7 (638-642).  
Refs: 15  
ISSN: 0951-418X CODEN: PHYREH  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English

09/836868

SUMMARY LANGUAGE: English

AB The emergence of resistant strains of Plasmodium falciparum and Mycobacterium tuberculosis underscores the need for novel drugs that are effective against these microorganisms. As part of our screening programme of the flora of Puerto Rico, we tested a number of ethanol extracts of higher plants for antiplasmodial and antimycobacterial activities. A total of 40 extracts belonging to 23 plant families and 37 species were tested for antiplasmodial activity. Five extracts demonstrated activity against Plasmodium falciparum in vitro (50%-100% parasite suppression at 5 .mu.g/mL). Another 63 extracts belonging to 30 plant families and 50 species were tested in vitro against Mycobacterium tuberculosis. Two extracts were found to be active, Ficus citrifolia and Pisonia borinquena (85% or more inhibition of microbial growth at 100 .mu.g/mL of extract).

Copyright .COPYRGT. 2001 John Wiley & Sons, Ltd.

L5 ANSWER 11 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 2001:499690 BIOSIS

DOCUMENT NUMBER: PREV200100499690

TITLE: Extracts of Morinda citrifolia (

noni) exhibit selective anti-tumor activity  
against breast and colon carcinoma cell lines.

AUTHOR(S): Csiszar, Katalin (1); Svertecki, Melinda; Ho,

Chi-Tang; Fong, Sheri F. T.

CORPORATE SOURCE: (1) Rutgers University, New Brunswick, NJ USA

SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2001) Vol. 42, pp. 634. print.

Meeting Info.: 92nd Annual Meeting of the American Association for Cancer Research New Orleans, LA, USA March 24-28, 2001

ISSN: 0197-016X.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

L5 ANSWER 12 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001175905 EMBASE

TITLE: [Noni juice - An amazing product?].

NONI - DER TAUSENDSSASSA?.

AUTHOR: Richter T.

CORPORATE SOURCE: Dr. T. Richter, Mohler-Apotheke, Burgstrasse 7, 97999 Igelsheim, Germany

SOURCE: Zeitschrift fur Phytotherapie, (2001) 22/2 (93).

ISSN: 0722-348X CODEN: ZPHYDG

COUNTRY: Germany

DOCUMENT TYPE: Journal; Note

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: German

L5 ANSWER 13 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001144569 EMBASE

TITLE: Traditional Hawaiian healing arts enrich conventional medical practices.

AUTHOR: Horowitz S.

SOURCE: Alternative and Complementary Therapies, (2001) 7/2 (68-73).

Refs: 21

09/836868

ISSN: 1076-2809 CODEN: ACTHFZ  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 017 Public Health, Social Medicine and  
Epidemiology  
030 Pharmacology  
037 Drug Literature Index

LANGUAGE: English  
SUMMARY LANGUAGE: English

AB Hawaii, with its lovely environment, generally healthful diet, and traditional Hawaiian folk medicine practices centered around a venerable tradition of respectfully utilizing plants for healing, in combination with the culture's contributions from TCM and other traditional modalities, has much to offer contemporary integrative medicine. The islands certainly provide a setting that is conducive to reestablishing physical, mental, and spiritual balance in one's life. Medicine practiced in Hawaii is part of a trend that seeks to be more culturally sensitive to traditional mind-body-spirit beliefs and uses of botanicals and massage. It is hoped that Hawaiian's enviable longevity statistics will not be deflated by the ubiquitous influx of unhealthful fast food restaurants and mainland Western modes of handling stress. Among Hawaii's botanical treasures, noni, in particular, warrants further scientific investigation to confirm and utilize further this plant's potential as an immune-system booster and supplementary anticancer agent. Thus, it is also hoped that heightened environmental consciousness will help to preserve native plants for their functional and inherent value. In the words of a staff member of the R.W. Bliss Army Health Center in Fort Huachuca, Arizona: "Hawaii will probably continue its role in the transition of plants from traditional use to conventional use".

L5 ANSWER 14 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001235047 EMBASE

TITLE: [Noni fruit].  
DIE NONI-FRUCHT.

AUTHOR: Langer R.

CORPORATE SOURCE: Dr. R. Langer, Institut fur Pharmakognosie,  
Universitat Wien, Pharmaziezentrum, Althanstrasse 14,  
A- 1090 Wien, Germany

SOURCE: Deutsche Apotheker Zeitung, (14 Jun 2001) 141/24  
(61-63).

Refs: 21

ISSN: 0011-9857 CODEN: DAZEA2.

COUNTRY: Germany

DOCUMENT TYPE: Journal; (Short Survey)

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: German

L5 ANSWER 15 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001364886 EMBASE

TITLE: [Noni - Questionable magic fruit from the South Seas].  
FRAGWURDIGE ZAUBERFRUCHT AUS DER SUDSEE.

AUTHOR: Seidemann J.

CORPORATE SOURCE: Dr. J. Seidemann, Neuendorfer Strasse 26/56, 14480  
Potsdam, Germany

SOURCE: Pharmazeutische Zeitung, (4 Oct 2001) 146/40 (36-40).  
Refs: 47

09/836868

ISSN: 0031-7136 CODEN: PZSED5  
COUNTRY: Germany  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: German

L5 ANSWER 16 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
ACCESSION NUMBER: 2000-248448 [22] WPIDS  
DOC. NO. CPI: C2000-075320  
TITLE: Preparation of composition based on extract of fruit of Polynesian plant Morinda Citrifolia, for use as invigorating-health improving drink, involves filtration, de-pectinization, heating and final filtration.  
DERWENT CLASS: D13 D16  
INVENTOR(S): TALON, C; TETUANUI, M  
PATENT ASSIGNEE(S): (ROYA-N) ROYAL TAHITI NONI SARL  
COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
FR 2783137	A1	20000317	(200022)*		6

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
FR 2783137	A1	FR 1998-11288	19980910

PRIORITY APPLN. INFO: FR 1998-11288 19980910

AN 2000-248448 [22] WPIDS

AB FR 2783137 A UPAB: 20000508

NOVELTY - A process for preparing a composition, based on extracts of plant MORINDA CITRIFOLIA (common name: 'nono') includes gathering fruit, grinding, sieving, pectin removal, heating, filtration and pasteurizing.

DETAILED DESCRIPTION - Process of preparation of composition containing extracts of active substances of plant MORINDA CITRIFOLIA comprises following stages:

- (a) gathering fruit at its 3rd or 4th maturity stage;
- (b) grinding washed fruit in centrifuge/grinder;
- (c) collecting of juice and filtration to eliminate froth and solids, by pressing through sieve or using extractor-press;
- (d) enzymatic pectin removal by adding pectin removing agent;
- (e) progressive heating of obtained liquid to 60-80 deg. C, preferably 70 deg. C, and maintaining it at this temperature for 1 minute;
- (f) filtration; and
- (g) pasteurizing filtered juice at 80-90 deg. C, preferably at 70 deg. C for 1 minute.

INDEPENDENT CLAIMS are also included for:

- (1) juice of nono fruit obtained using process as claimed; and
- (2) use of juice of nono obtained as claimed, in pure form or diluted in other fruit juice, as health improving/invigorating drink.

USE - On its own or in mixture with various fruit juices, as

09/836868

invigorating drink regulating natural body functions and having /  
hypotensive, anti-ulcer, antiseptic, laxative etc. properties.

ADVANTAGE - The product is stable on storage, has no unpleasant  
odor and retains properties of naturally obtained extracts.

Dwg.0/0

L5 ANSWER 17 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 2000315612 EMBASE  
TITLE: Novel glycosides from noni (*Morinda citrifolia*).  
AUTHOR: Wang M.; Kikuzaki H.; Jin Y.; Nakatani N.; Zhu N.;  
Csiszar K.; Boyd C.; Rosen R.T.; Ghai G.; Ho C.-T.  
CORPORATE SOURCE: C.-T. Ho, Department of Food Science, Center for  
Advanced Food Technology, Rutgers University, 65  
Dudley Road, New Brunswick, NJ 08901-8520, United  
States. ho@aesop.rutgers.edu  
SOURCE: Journal of Natural Products, (2000) 63/8 (1182-1183).  
Refs: 12  
ISSN: 0163-3864 CODEN: JNPRDF  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
AB Three new glycosides were isolated from the fruits of noni (*Morinda citrifolia*). Their structures were determined to be  
6-O-(.beta.-D-glucopyranosyl)-1-O-octanoyl-.beta.-D-glucopyranose  
(1), 6-O-(.beta.-D-glucopyranosyl)-1-O-hexanoyl-.beta.-D-  
glucopyranose (2), and 3-methylbut-3-enyl 6-O-.beta.-D-  
glucopyranosyl-.beta.-D-glucopyranoside (3) using MS and NMR  
methods.

L5 ANSWER 18 OF 33 CABO COPYRIGHT 2001 CABI  
ACCESSION NUMBER: 2001:106961 CABO  
DOCUMENT NUMBER: 20013101436  
TITLE: To trace the active compound in mengkudu  
(*Morinda citrifolia*) with anthelmintic  
activity against *Haemonchus contortus*  
Penulusuran senyawa aktif dari buah mengkudu  
(*Morinda citrifolia*) dengan aktivitas  
antelmintik terhadap *Haemonchus contortus*  
AUTHOR: Murdiati, T. B.; Adiwinata, G.; Hildasari, D.  
CORPORATE SOURCE: Balai Penelitian Veteriner, Jalan R.E.  
Martadinata No.30, P.O. Box 151, Bogor 16114,  
Indonesia.  
SOURCE: Jurnal Ilmu Ternak dan Veteriner, (2000) Vol.  
5, No. 4, pp. 255-259. 15 ref.  
ISSN: 0853-7380  
DOCUMENT TYPE: Journal  
LANGUAGE: Indonesian  
SUMMARY LANGUAGE: English  
AB To trace the active compounds responsible for the anthelmintic  
activity against *H. contortus*, the mengkudu fruit *Morinda citrifolia* was continuously extracted into hexane,  
chloroform, metanol and water, followed by in-vitro study on the  
anthelmintic activity. The in-vitro activity was based on the  
ability of the extracts to kill the worm and the ability of the  
extracts to prevent egg development. The results suggests that  
chloroform fraction which contains alkaloid and anthraquinon have

09/836868

the highest anthelmintic activity and showed significant difference to that of the control ( $P<0.05$ ).

L5 ANSWER 19 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 1999298923 EMBASE  
TITLE: An immunomodulatory polysaccharide-rich substance from the fruit juice of *Morinda citrifolia* (noni) with antitumour activity.  
AUTHOR: Hirazumi A.; Furusawa E.  
CORPORATE SOURCE: Dr. E. Furusawa, Department of Pharmacology, John A. Burns School of Medicine, University of Hawaii, 1960 East West Road, Honolulu, HI 96822, United States  
SOURCE: Phytotherapy Research, (1999) 13/5 (380-387).  
Refs: 36  
ISSN: 0951-418X CODEN: PHYREH  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 016 Cancer  
026 Immunology, Serology and Transplantation  
030 Pharmacology  
037 Drug Literature Index  
039 Pharmacy  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
AB The fruit juice of *Morinda citrifolia* (noni) contains a polysaccharide-rich substance (noni-ppt) with antitumour activity in the Lewis lung (LLC) peritoneal carcinomatosis model. Therapeutic administration of noni-ppt significantly enhanced the duration of survival of inbred syngeneic LLC tumour bearing mice. It did not exert significant cytotoxic effects in an adapted culture of LLC cells, LLC1, but could activate peritoneal exudate cells (PEC) to impart profound toxicity when co-cultured with the tumour cells. This suggested the possibility that noni-ppt may suppress tumour growth through activation of the host immune system. Concomitant treatment with the immunosuppressive agent, 2-chloroadenosine (C1-Ade) or cyclosporin (cys-A) diminished its activity, thereby substantiating an immunomodulatory mechanism. Noni-ppt was also capable of stimulating the release of several mediators from murine effector cells, including tumour necrosis factor-.alpha. (TNF-.alpha.), interleukin-1.beta. (IL-1.beta.), IL-10, IL-12 p70, interferon-.gamma. (IFN-.gamma.) and nitric oxide (NO), but had no effect on IL-2 and suppressed IL-4 release. Improved survival time and curative effects occurred when noni-ppt was combined with sub-optimal doses of the standard chemotherapeutic agents, adriamycin (Adria), cisplatin (CDDP), 5-fluorouracil (5-FU), and vincristine (VCR), suggesting important clinical applications of noni-ppt as a supplemental agent in cancer treatment.

L5 ANSWER 20 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 2000023673 EMBASE  
TITLE: Evaluation of the flora of Puerto Rico for in vitro cytotoxic and anti-HIV activities.  
AUTHOR: Antoun M.D.; Martinez E.; Caballero R.; Oquendo I.; Proctor G.R.; Weislow O.S.; McCloud T.G.; Kiser R.; Staley P.; Clanton D.  
CORPORATE SOURCE: M.D. Antoun, Department Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan 00936, Puerto Rico

09/836868

SOURCE: Pharmaceutical Biology, (1999) 37/4 (277-280).

Refs: 23

ISSN: 1388-0209 CODEN: PHBIFC

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 004 Microbiology

016 Cancer

030 Pharmacology

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB A total of 38 plant species belonging to 29 families were screened against HIV at the National Cancer Institute, Frederick Cancer Research and Development Center. In this assay, the virus is replicated in CEM SS cells, which are malignant cells of lymphocytic origin. It is therefore possible to measure the cytotoxicity of the extracts simultaneously, which is indicative of possible anticancer activity. Anti-HIV activity was found in eight extracts, whereas 13 extracts demonstrated cytotoxicity at an IC50 of 25 .mu.g/ml or less.

L5 ANSWER 21 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
DUPLICATE 3

ACCESSION NUMBER: 1996-439483 [44] WPIDS

DOC. NO. CPI: C1996-138146

TITLE: anti-helicobacter pylori agent contg.

extract of dried roots of Morinda citrifolia - is used to treat recurring infection diseases of upper respiratory tract caused by Helicobacter pylori e.g. peptic ulcers.

DERWENT CLASS: B04

PATENT ASSIGNEE(S): (TERU) TERUMO CORP

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 08217686	A	19960827	(199644)*		3

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 08217686	A	JP 1995-20633	19950208

PRIORITY APPLN. INFO: JP 1995-20633 19950208

AN 1996-439483 [44] WPIDS

AB JP 08217686 A UPAB: 19961104

Agent contains extract of dried roots of Morinda citrifolia.

Dried Morinda citrifolia roots are extracted with organic solvent (e.g. EtOH, n-BuOH, pyridine, hexane, EtOAc, acetone, pref. MeOH and CHCl<sub>3</sub>) for 1-2 days. Extract is evaporated and used for producing of oral and parenteral preps. with conventional carriers and additives. USE/ADVANTAGE - Used to eradicate helicobacter pylori. Dosage is 0.10-3000 (pref. 1-1000) mg/day for adult patients in 1-4 divided doses. Treats and prevents

09/836868

recurrence of upper digestive tract infectious diseases caused by *Helicobacter pylori* (e.g. peptic ulcer, gastritis and hepatitis, and gastric and hepatic cancers).

In an example, extract of dried *Morinda citrifolia* roots exhibited MIC of 6.25 mg/ml against *Helicobacter pylori* and showed acute oral toxicity, LD50 to male 5-week-old ICR mice of over 1000 mg/kg.

Dwg.0/0

L5 ANSWER 22 OF 33 JAPIO COPYRIGHT 2001 JPO  
ACCESSION NUMBER: 1996-208461 JAPIO  
TITLE: ANTI-HELICOBACTER PYRORI AGENT  
INVENTOR: HASEGAWA HIROKAZU; KOYANO TAKASHI  
PATENT ASSIGNEE(S): TERUMO CORP, JP (CO 365358)  
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 08208461	A	19960813	Heisei	(6) A61K031-12

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1995-20630 19950208  
ORIGINAL: JP07020630 Heisei  
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 96, No. 8

AN 1996-208461 JAPIO

AB PURPOSE: To obtain the subject agent having anti-*Helicobacter pyrori* action and useful as an agent for the treatment and the relapse prevention of digestive ulcer, gastritis and hepatitis.  
CONSTITUTION: This anti-*Helicobacter pyrori* agent contains nordamnacanthal of formula I or damnacanthal of formula II. Nordamnacanthal is an orange acicular crystal having a melting point of 215.5-219.0.degree.C (recrystallized from CHCl<sub>3</sub>-hexane) and damnacanthal is a yellow acicular crystal having a melting point of 215.0-216.9.degree.C (recrystallized from CHCl<sub>3</sub>-hexane). The compounds of formula I and formula II can be produced by extracting dried roots of *Morinda citrifolia* with an organic solvent (preferably MeOH or CHCl<sub>3</sub>) or water at room temperature or under heating preferably after pulverizing the roots, filtering the extract and distilling out the solvent from the filtrate under reduced pressure. The daily administration rate of the agent for adult is generally 0.10-3,000mg, preferably 1-1,000mg divided in 1-4 divided portions.

L5 ANSWER 23 OF 33 SCISEARCH COPYRIGHT 2001 ISI (R)

ACCESSION NUMBER: 96:100186 SCISEARCH

THE GENUINE ARTICLE: TR362

TITLE: MUTAGENESIS OF SER(41) TO ALA INHIBITS THE ASSOCIATION OF GAP-43 WITH THE MEMBRANE SKELETON OF GAP-43-DEFICIENT PC12B CELLS - EFFECTS ON CELL-ADHESION AND THE COMPOSITION OF NEURITE CYTOSKELETON AND MEMBRANE

AUTHOR: MEIRI K F (Reprint); HAMMANG J P; DENT E W; BAETGE E E

CORPORATE SOURCE: SUNY HLTH SCI CTR, DEPT PHARMACOL, SYRACUSE, NY, 13210 (Reprint); SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, SYRACUSE, NY, 13210; CYTOTHERAPEUT INC,

09/836868

COUNTRY OF AUTHOR: PROVIDENCE, RI, 02906  
USA  
SOURCE: JOURNAL OF NEUROBIOLOGY, (FEB 1996) Vol. 29, No. 2,  
pp. 213-232.  
ISSN: 0022-3034.  
DOCUMENT TYPE: Article; Journal  
FILE SEGMENT: LIFE  
LANGUAGE: ENGLISH  
REFERENCE COUNT: 63

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB To investigate the molecular basis for GAP-43 function in axon outgrowth, we produced a mutant, GAP-43 (Ala(41)), whose interaction with calmodulin in vitro was unaffected by increasing Ca<sup>2+</sup> concentrations, and stably transfected it into GAP-43-deficient PC12B cells. Several lines that expressed wild-type or mutant protein at levels that resembled endogenous GAP-43 expression in PC12 controls were subcloned and characterized. GAP-43 (Ala(41)) was significantly more extractable with Noni-det P-40 and less tightly associated with the membrane skeleton than the wild-type protein. Furthermore, GAP-43 (Ala(41)) expression by PC12B cells profoundly affected their phenotype: First, observation of living cells using video-enhanced microscopy revealed irregular plasma membranes with numerous blebs and protrusions and neurites that appeared thin and varicose. Second, both the cells' ability to remain attached to laminin substrates and the amount of alpha 1 beta 1 integrin expressed on the cell surface was significantly decreased. Finally, peripherin transport, which is abnormal in PC12B cells, could be rescued by transfection of wild-type GAP-43 but not the GAP-43(Ala(41)) mutant. The phenotypic abnormalities resemble other cell types in which membrane skeleton/plasma membrane interactions have been functionally decoupled, and our results are consistent with the notion that these interactions may be abnormal in GAP-43(Ala(41))-expressing PC12B cells, either as a direct consequence of the mutation or arising secondarily to the altered availability of calmodulin in the growing neurite. (C) 1996 John Wiley & Sons, Inc.

L5 ANSWER 24 OF 33 JAPIO COPYRIGHT 2001 JPO  
ACCESSION NUMBER: 1994-087737 JAPIO  
TITLE: ANTI-AIDS AGENT  
INVENTOR: KOYANO TAKASHI; IIDA KUMIKO; ASANO KAORU;  
YOSHIZAWA MASAO; UMEZAWA KAZUO  
PATENT ASSIGNEE(S): TONEN CORP, JP (CO 352374)  
UMEZAWA KAZUO, JP (IN)

PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 06087737	A	19940329	Heisei	(5) A61K031-12

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1992-264312 19920907  
ORIGINAL: JP04264312 Heisei  
SOURCE: PATENT ABSTRACTS OF JAPAN, Unexamined  
Applications, Section: C, Sect. No. 1219, Vol.  
18, No. 347, P. 88 (19940630)

AN 1994-087737 JAPIO

09/836868

AB PURPOSE: To obtain an anti-AIDS agent having activity capable of suppressing proliferation of HIV in infected cell.  
CONSTITUTION: The anti-AIDS agent contains 1-methoxy-2-formyl-3-hydroxyanthraquinone expressed by the formula as an active ingredient. This compound is obtained by extracting *Morinda citrifolia* of a tropical plant, preferably with a non-polar solvent, especially a hydrocarbon solvent or a halogenated hydrocarbon solvent and concentrating the resultant extract once and then purifying the extract by chromatography. This anti-AIDS agent is mainly orally administered and its dose is 50-500mg/1kg body daily.

L5 ANSWER 25 OF 33 JAPIO COPYRIGHT 2001 JPO  
ACCESSION NUMBER: 1994-087736 JAPIO  
TITLE: ANTICANCER AGENT  
INVENTOR: UMEZAWA KAZUO; IMOTO MASAYA; OBA SHIGERU; KOYANO TAKASHI; KOMIYAMA YOSHIKO  
PATENT ASSIGNEE(S): UMEZAWA KAZUO, JP (IN)  
TONEN CORP, JP (CO 352374)

PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 06087736	A	19940329	Heisei	(5) A61K031-12

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1992-264311 19920907  
ORIGINAL: JP04264311 Heisei  
SOURCE: PATENT ABSTRACTS OF JAPAN, Unexamined Applications, Section: C, Sect. No. 1219, Vol. 18, No. 347, P. 88 (19940630)

AN 1994-087736 JAPIO

AB PURPOSE: To obtain an anticancer agent containing 1-methoxy-2formyl-3- hydroxyanthraquinone obtained from extract of *Morinda citrifolia* which is a tropical plant as an active ingredient.  
CONSTITUTION: *Morinda citrifolia* naturally grown or partially cultured in Southeast Asia is extracted with a solvent such as chloroform at ambient temperature to 60.degree.C to afford 1-methoxy-2-formyl-3-hydroxyanthraquinone of the formula. Using this compound as an active ingredient, the objective anticancer agent is provided. This active ingredient exhibits action capable of inhibiting action of ras cancer gene product. Namely, this active ingredient exhibits activity capable of inhibiting proliferation of cancer cell and normalizing the form of the cell.

L5 ANSWER 26 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS  
ACCESSION NUMBER: 1993:269525 BIOSIS  
DOCUMENT NUMBER: PREV199344131675  
TITLE: The effect of noni fruit extract (*Morinda citrifolia*, Indian mulberry) on thymocytes of BALB/C mouse.  
AUTHOR(S): Ganal, C. A.; Hokama, Y.  
CORPORATE SOURCE: Dep. Pathol., John A. Burns Sch. Med., Univ. Hawaii, Honolulu, HI 96822  
SOURCE: FASEB Journal, (1993) Vol. 7, No. 3-4, pp. A866.  
Meeting Info.: Meeting of the Federation of American

09/836868

Societies for Experimental Biology on Experimental  
Biology '93 New Orleans, Louisiana, USA March  
28-April 1, 1993  
ISSN: 0892-6638.

DOCUMENT TYPE: Conference  
LANGUAGE: English

L5 ANSWER 27 OF 33 SCISEARCH COPYRIGHT 2001 ISI (R)  
ACCESSION NUMBER: 93:147964 SCISEARCH  
THE GENUINE ARTICLE: KP975  
TITLE: THE EFFECT OF NONI FRUIT EXTRACT  
(MORINDA-CITRIFOLIA, INDIAN  
MULBERRY) ON THYMOCYTES OF BALB/C MOUSE  
AUTHOR: GANAL C A (Reprint); HOKAMA Y  
CORPORATE SOURCE: UNIV HAWAII, JOHN A BURNS SCH MED, DEPT PATHOL,  
HONOLULU, HI, 96822  
COUNTRY OF AUTHOR: USA  
SOURCE: FASEB JOURNAL, (23 FEB 1993) Vol. 7, No. 4, Part 2,  
pp. A866.  
ISSN: 0892-6638.  
DOCUMENT TYPE: Conference; Journal  
FILE SEGMENT: LIFE  
LANGUAGE: ENGLISH  
REFERENCE COUNT: 1

L5 ANSWER 28 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS  
ACCESSION NUMBER: 1993:400179 BIOSIS  
DOCUMENT NUMBER: PREV199345059004  
TITLE: Isolation of a ras-function inhibitor from an  
extract of the tropical plant Morinda  
citrifolia.  
AUTHOR(S): Umezawa, K. (1); Hiramatsu, T.; Imoto, M.; Koyano, T.  
CORPORATE SOURCE: (1) Dep. Applied Chem., Keio Univ., Yokohama 223  
Japan  
SOURCE: Proceedings of the American Association for Cancer  
Research Annual Meeting, (1993) Vol. 34, No. 0, pp.  
386.  
Meeting Info.: 84th Annual Meeting of the American  
Association for Cancer Research Orlando, Florida, USA  
May 19-22, 1993  
ISSN: 0197-016X.  
DOCUMENT TYPE: Conference  
LANGUAGE: English

L5 ANSWER 29 OF 33 CABO COPYRIGHT 2001 CABO  
ACCESSION NUMBER: 94:108744 CABO  
DOCUMENT NUMBER: 940308520  
TITLE: A new anthraquinone glycoside from [heartwood  
of] Morinda citrifolia  
AUTHOR: Mala Srivastava; Singh, J.; Srivastava, M.  
CORPORATE SOURCE: Department of Chemistry, University of  
Allahabad, Allahabad 211 002, India.  
SOURCE: International Journal of Pharmacognosy, (1993)  
Vol. 31, No. 3, pp. 182-184. 10 ref.  
ISSN: 0925-1618  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB M. citrifolia roots are used to relieve the pain caused by gout, and

09/836868

for their cathartic and febrifuge properties; leaves are used to treat wounds and ulcers, and the fruits are used to treat spongy gums, leucorrhoea and sapraemia. Physcion, morindone, and the new anthraquinone glycoside, physcion-8-O-[{ alpha -L-arabinopyranosyl(1 right arrow 3)}{ beta -D-galactopyranosyl(1 right arrow 6)}- beta -D-galactopyranoside], were isolated from the EtOH extract of the heartwood of *M. citrifolia* (collected from Allahabad, Uttar Pradesh, India), and identified from spectral analysis.

L5 ANSWER 30 OF 33 MEDLINE DUPLICATE 4  
ACCESSION NUMBER: 94036765 MEDLINE  
DOCUMENT NUMBER: 94036765 PubMed ID: 7693328  
TITLE: Induction of normal phenotypes in ras-transformed cells by damnacanthal from *Morinda citrifolia*.  
AUTHOR: Hiramatsu T; Imoto M; Koyano T; Umezawa K  
CORPORATE SOURCE: Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan.  
SOURCE: CANCER LETTERS, (1993 Sep 30) 73 (2-3) 161-6.  
JOURNAL code: CMX; 7600053. ISSN: 0304-3835.  
PUB. COUNTRY: Ireland  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199311  
ENTRY DATE: Entered STN: 19940117  
Last Updated on STN: 19960129  
Entered Medline: 19931126

AB We have screened tropical plant extracts for substances that induce normal morphology in K-rasts-NRK cells. As a result we isolated an anthraquinone compound, damnacanthal, from the chloroform extract of the root of *Morinda citrifolia*. Damnacanthal induced normal morphology and cytoskeletal structure in K-rasts-NRK cells at the permissive temperature, without changing the amount and localization of Ras. The effect of damnacanthal was reversible, and the compound had no effect on the morphology of RSVts-NRK cells expressing the src oncogene. Thus, damnacanthal is a new inhibitor of ras function.

L5 ANSWER 31 OF 33 MEDLINE DUPLICATE 5  
ACCESSION NUMBER: 91172909 MEDLINE  
DOCUMENT NUMBER: 91172909 PubMed ID: 1981810  
TITLE: Analgesic and behavioural effects of *Morinda citrifolia*.  
AUTHOR: Younos C; Rolland A; Fleurentin J; Lanher M C;  
Misslin R; Mortier F  
CORPORATE SOURCE: Laboratoire de Pharmacognosie, Universite de Metz, France.  
SOURCE: PLANTA MEDICA, (1990 Oct) 56 (5) 430-4.  
Journal code: P9F; 0066751. ISSN: 0032-0943.  
PUB. COUNTRY: GERMANY: Germany, Federal Republic of  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199104  
ENTRY DATE: Entered STN: 19910512  
Last Updated on STN: 19950206  
Entered Medline: 19910425

09/836868

AB The traditional therapeutic indications for the use of *Morinda citrifolia* L. (Rubiaceae) have been investigated. The lyophilised aqueous extract of roots of *M. citrifolia* was evaluated for analgesic and behavioural effects in mice. The extract did not exhibit any toxic effects but did show a significant, dose-related, central analgesic activity in the writhing and hotplate tests; this effect was confirmed by the antagonistic action of naloxone. Furthermore, administration of *M. citrifolia* extract at high dosages decreased all behavioural parameters in the two compartment test, the light/dark choice situation test, and the staircase test; together with the induced sleeping time, these results are suggestive of sedative properties.

L5 ANSWER 32 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
ACCESSION NUMBER: 1987-203558 [29] WPIDS  
DOC. NO. CPI: C1987-085328  
TITLE: Compsn. for treatment of hepatitis - contains asperulosidic acid extracted from *Morinda citrifolia* L bark as active component.  
DERWENT CLASS: A96 B02  
PATENT ASSIGNEE(S): (EISA) EISAI CO LTD  
COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 62132829	A	19870616 (198729)*			3

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 62132829	A	JP 1985-272397	19851205

PRIORITY APPLN. INFO: JP 1985-272397 19851205

AN 1987-203558 [29] WPIDS

AB JP 62132829 A UPAB: 19930922

Remedy for hepatitis contains asperulosidic acid as an active substance.

The effect of asperulosidic acid was found in a rat acute hepatopathy model induced by D-galactosamine and having resemblance to human viral hepatitis histologically. Asperulosidic acid is extracted from *Morinda citrifolia* L. 35 kg of fresh bark of *Morinda citrifolia* L. is soaked in 25 lit. of methanol for 4 days. Methanol is removed from the extract and the obtd. 1 kg of residue is extracted with n-butanol. n-Butanol is removed from the extract and the obtained residue (170 g) is subjected to silica gel column chromatography. Fractions which exhibits blue in sulphuric acid reaction after TLC are collected and asperulosidic acid is recrystallised.

The structure of asperulosidic acid is of formula (I).

In an example asperulosidic acid (5 g), microcrystalline cellulose (80 g), corn starch (20 g), lactose (22 g) and polyvinylpyrrolidone (3 g) were granulated and filled in capsules to obtain the remedy.

USE/ADVANTAGE - Hepatitis is viral hepatitis, alcoholic hepatitis or drug-induced hepatitis.

09/836868

0/0

L5 ANSWER 33 OF 33 CABA COPYRIGHT 2001 CABI  
ACCESSION NUMBER: 80:11733 CABA  
DOCUMENT NUMBER: 800381244  
TITLE: Some chemical constituents of *Morinda citrifolia*  
AUTHOR: Levand, O.; Larson, H. O.  
CORPORATE SOURCE: University of Guam, Agana, Guam 96910.  
SOURCE: *Planta Medica*, (1979) Vol. 36, No. 2, pp. 186-187. 14 ref.  
ISSN: 0032-0943  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Asperuloside and glucose were identified in extracts of dried *M. citrifolia* fruits. Caproic acid and caprylic acid were also found.

~~FILE 'FSTA' ENTERED AT 10:04:51 ON 21 DEC 2001~~  
L6 2 S L3

L6 ANSWER 1 OF 2 FSTA COPYRIGHT 2001 IFIS  
ACCESSION NUMBER: 2001(10):J2545 FSTA FS FSTA  
TITLE: *Morinda citrifolia* dietary fiber and method.  
AUTHOR: Wadsworth, J. J.; Story, S. P.; Jensen, C. J.  
CORPORATE SOURCE: Morinda Inc.  
SOURCE: United States Patent  
PATENT INFORMATION: US 6254913 B1 2001  
PRIORITY APPLN. INFO: US 99-384784 27 Aug. 1999 (Morinda, Provo, UT, USA)  
DOCUMENT TYPE: Patent (Patent)  
LANGUAGE: English  
AB A dietary fibre product produced from the Indian mulberry (*Morinda citrifolia*) plant, and a process of extracting and purifying the fibre, are described. The Indian mulberry pulp is washed and separated from its juice by filtration. The wet pulp is then pasteurized, and can be further processed by drying. A high fibre product can be obtained by mixing the pulp with ingredients such as supplemental dietary fibre, water, sweeteners, flavouring agents, coloring agents and nutritional ingredients.

L6 ANSWER 2 OF 2 FSTA COPYRIGHT 2001 IFIS  
ACCESSION NUMBER: 2000(06):H1431 FSTA FS FSTA  
TITLE: [Product based on extracts of *Morinda citrifolia*.]  
AUTHOR: Talon, C.; Tetuanui, M.  
CORPORATE SOURCE: Royal Tahiti Noni sarl  
SOURCE: French Patent Application  
PATENT INFORMATION: FR 2783137 A1 2000  
PRIORITY APPLN. INFO: FR 98-11288 10 Sep. 1998  
DOCUMENT TYPE: Patent (Patent)  
LANGUAGE: French  
AB A process is described for extraction of active principles from noni fruit (*Morinda citrifolia*); this extract may be filtered, depectinated, heated, re-filtered and used directly as a beverage or blended with fruit juices.

=> fil hom

09/836868

FILE 'HOME' ENTERED AT 10:05:21 ON 21 DEC 2001

Searcher : Shears 308-4994

09/836868

(FILE 'MEDLINE', BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,  
JICST-EPLUS, JAPIO, CABA, AGRICOLA, CROPU, CROPB, LIFESCI, FSTA'  
ENTERED AT 10:38:06 ON 21 DEC 2001)

L11 O S L1

=> fil hom  
FILE 'HOME' ENTERED AT 10:38:42 ON 21 DEC 2001